SGEN - Seattle Genetics, Inc.
| Previous Close | 63.18 |
| Open | 69.89 |
| Bid | 74.82 x 800 |
| Ask | 74.86 x 1200 |
| Day's Range | 69.00 - 75.04 |
| 52 Week Range | 50.71 - 84.37 |
| Volume | 3,762,942 |
| Avg. Volume | 784,596 |
| Market Cap | 11.809B |
| Beta (3Y Monthly) | 1.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.78 |
| Earnings Date | Jul 24, 2019 - Jul 29, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 79.46 |
- Motley Fool•33 minutes ago
Here's Why Seattle Genetics Rocketed Higher Today
Sales growth of the biotech's blood cancer drug Adcetris rebounded.
- Zacks•2 hours ago
Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates
Seattle Genetics (SGEN) betters loss estimates and rides high on revenue beat in Q2.
- Thomson Reuters StreetEvents•6 hours ago
Edited Transcript of SGEN earnings conference call or presentation 16-Jul-19 8:30pm GMT
Q2 2019 Seattle Genetics Inc Earnings Call
Motley Fool•11 hours agoSeattle Genetics Inc (SGEN) Q2 2019 Earnings Call Transcript
SGEN earnings call for the period ending June 30, 2019.
- Zacks•19 hours ago
Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates
Seattle Genetics (SGEN) delivered earnings and revenue surprises of 38.46% and 14.25%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Investor's Business Daily•20 hours ago
The Surprising Reason This Biotech Stock Got An After-Hours Boost
Seattle Genetics stock popped late Tuesday after the biotech company topped second-quarter revenue estimates. But the company's losses per share were deeper than expected for the period.
- Business Wire•21 hours ago
Seattle Genetics Reports Second Quarter 2019 Financial Results
-Record ADCETRIS® Net Sales in U.S. and Canada of $159.0 Million in the Second Quarter, an Increase of 30 Percent Over the Second Quarter of 2018-
- ACCESSWIRE•22 hours ago
Seattle Genetics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / July 16, 2019 / Seattle Genetics, Inc. (NASDAQ: SGEN ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 16, 2019 at 4:30 PM ...
- PR Newswire•yesterday
Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
TOKYO and BOTHELL, Wash., July 16, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seattle Genetics, Inc. (SGEN) today announced submission of a Biologics License Application for accelerated approval to the U.S. Food and Drug Administration for the investigational agent enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who have received a PD-1/L1 inhibitor and who have received a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. The submission is based on results from the first cohort of patients in the EV-201 pivotal phase 2 clinical trial that were presented as a late-breaking abstract at the annual meeting of the American Society of Clinical Oncology (ASCO) in June.
- Business Wire•yesterday
Seattle Genetics and Astellas Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
Seattle Genetics, Inc. (SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced submission of a Biologics License Application for accelerated approval to the U.S. Food and Drug Administration for the investigational agent enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who have received a PD-1/L1 inhibitor and who have received a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. The submission is based on results from the first cohort of patients in the EV-201 pivotal phase 2 clinical trial that were presented as a late-breaking abstract at the annual meeting of the American Society of Clinical Oncology (ASCO) in June.
- Benzinga•4 days ago
The Week Ahead In Biotech: Johnson & Johnson Kickstarts Big Pharma Earnings
Last week was a quiet one for the biotech space with the exception of a few clinical trial readouts . Pharma and biotech stocks took comfort in a ruling by a federal judge that went against President Donald ...
- Simply Wall St.•4 days ago
Brief Commentary On Seattle Genetics, Inc.'s (NASDAQ:SGEN) Fundamentals
Attractive stocks have exceptional fundamentals. In the case of Seattle Genetics, Inc. (NASDAQ:SGEN), there's is a...
- GuruFocus.com•6 days ago
Seattle Genetics Inc (SGEN) President and CEO Clay B Siegall Sold $1.3 million of Shares
President and CEO of Seattle Genetics Inc (SGEN) Clay B Siegall sold 20,148 shares of SGEN on 07/08/2019 at an average price of $66.89 a share.
- Zacks•8 days ago
Earnings Preview: Seattle Genetics (SGEN) Q2 Earnings Expected to Decline
Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire•15 days ago
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2019 Financial Results on July 16, 2019
Seattle Genetics, Inc. announced today that it will report its second quarter 2019 financial results on Tuesday, July 16, 2019 after the close of financial markets. Following the announcement, management will host a conference call and webcast discussion of the results and provide a general corporate update.
- PR Newswire•23 days ago
Natasha A. Hernday Elected to PDL BioPharma's Board of Directors
INCLINE VILLAGE, Nev., June 24, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (PDLI) announces that at its 2019 annual meeting of stockholders held June 20, 2019, the Company's stockholders elected Natasha A. Hernday to the Company's Board of Directors. The Company also announced that its stockholders voted to re-elect Harold E. Selick, Ph.D. and Samuel R. Saks, M.D. as Directors, and approved, on an advisory basis, executive officer compensation.
- American City Business Journals•27 days ago
Clay Siegall continues Seattle Genetics' fast expansion, growth
Puget Sound Business Journal has named Clay Sigall its Middle Market Dealmaker of the Year for the inaugural Middle Market Fast 50 event and section.
- Insider Monkey•28 days ago
Here’s What Hedge Funds Think About Seattle Genetics, Inc. (SGEN)
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Jeff Ubben, George Soros and Carl Icahn think. Those hedge fund operators make billions of […]
- Markit•29 days ago
See what the IHS Markit Score report has to say about Seattle Genetics Inc.
Seattle Genetics Inc NASDAQ/NGS:SGENView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for SGEN with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on May 29. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding SGEN is favorable, with net inflows of $4.58 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•29 days ago
Roche's Rozlytrek Gets Approval in Japan for Solid Tumors
Roche's (RHHBY) oncology portfolio gets a boost with the approval of Rozlytrek for neurotrophic tyrosine receptor kinase fusion-positive, advanced recurrent solid tumors.
- Simply Wall St.•last month
Does Seattle Genetics, Inc.'s (NASDAQ:SGEN) CEO Salary Compare Well With Others?
Clay Siegall became the CEO of Seattle Genetics, Inc. (NASDAQ:SGEN) in 2002. This analysis aims first to contrast CEO...
- Business Wire•last month
Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the Congress of the European Hematology Association (EHA) and the International Conference on Malignant Lymphoma (ICML)
-Data Presentations Highlight Continued Advances in Research for Treating Blood Cancers-
- Zacks•last month
Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II
Roche's (RHHBY) hematology portfolio gets a boost as FDA approves Polivy for DLBCL, and lymphoma drug, Gazyva, meets goals in a phase II study.
- Business Wire•last month
Seattle Genetics’ Antibody-Drug Conjugate Technology Utilized in Genentech’s Polivy, Now Approved by FDA
Seattle Genetics, Inc. (SGEN) today announced U.S. Food and Drug Administration (FDA) approval of Polivy™ (polatuzumab vedotin-piiq), which is an antibody-drug conjugate (ADC) targeting CD79b that utilizes Seattle Genetics’ technology. Polivy was developed and will be commercialized by Genentech, a member of the Roche Group. Polivy previously received FDA Breakthrough Therapy Designation, and was approved more than two months ahead of the Prescription Drug User Fee Act (PDUFA) action date of August 19, 2019.
